An Open-label Treatment Study to Evaluate the Safety, Tolerability and Efficacy of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias.
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Mavoglurant (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Novartis
- 23 Sep 2014 Trial status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 19 Oct 2012 Planned number of patients changed from 119 to 244.